Table 1.

Patient characteristics

Therapy
Baseline eosinophil count, × 109/L*
Serum IL-5 level, ng/mL
Bone marrow biopsy cellularity, %
Granulocytic precursors in bone marrow aspirate, %
Patient
Sex
Age, y
Clinical manifestations
Prior to study
During study
F/P mutation†
Before
After 3 d
After 1 mo
Before
After 1 mo
After last dose
Before
After 1 mo
After last dose
1   M   52   Mucosal ulcerations, dermatitis, splenomegaly   P, HU, IFN   HU   3.630   Yes   2   < 1.95   3.3   70   50   30   58   68   76  
2   F   32   Angioedema, dermatitis, myoedema, arthralgias, myalgias   P, HU, IFN   P   2.620   No   2   < 1.95   6.1   55   60   60   80   70   78  
3   M   38   Mucosal ulcerations, dermatitis, anemia, thrombocytopenia, splenomegaly   P, HU, IFN   P, HU IFN   6.133   Yes   < 1.95   < 1.95   < 1.95   95   95   NA   ND   41   NA  
4
 		 F
 		 47
 		 Pericarditis, pleuritis, urticaria, cerebrovascular accident, digital ulcerations
 		 P, HU, IFN, Im
 		 HU
 		 3.209
 		 No
 		 223
 		 14.5
 		 24.4
 		 40
 		 40
 		 NA
 		 61
 		 34
 		 NA
 
Therapy
Baseline eosinophil count, × 109/L*
Serum IL-5 level, ng/mL
Bone marrow biopsy cellularity, %
Granulocytic precursors in bone marrow aspirate, %
Patient
Sex
Age, y
Clinical manifestations
Prior to study
During study
F/P mutation†
Before
After 3 d
After 1 mo
Before
After 1 mo
After last dose
Before
After 1 mo
After last dose
1   M   52   Mucosal ulcerations, dermatitis, splenomegaly   P, HU, IFN   HU   3.630   Yes   2   < 1.95   3.3   70   50   30   58   68   76  
2   F   32   Angioedema, dermatitis, myoedema, arthralgias, myalgias   P, HU, IFN   P   2.620   No   2   < 1.95   6.1   55   60   60   80   70   78  
3   M   38   Mucosal ulcerations, dermatitis, anemia, thrombocytopenia, splenomegaly   P, HU, IFN   P, HU IFN   6.133   Yes   < 1.95   < 1.95   < 1.95   95   95   NA   ND   41   NA  
4
 		 F
 		 47
 		 Pericarditis, pleuritis, urticaria, cerebrovascular accident, digital ulcerations
 		 P, HU, IFN, Im
 		 HU
 		 3.209
 		 No
 		 223
 		 14.5
 		 24.4
 		 40
 		 40
 		 NA
 		 61
 		 34
 		 NA
 

P indicates prednisone; HU, hydroxyurea; IFN, interferon-α, NA, not applicable; ND, not done; and Im, imatinib mesylate.

*

Normal range of eosinophils, 0 × 109/L to 0.750 × 109/L (0/mm3 to 750/mm3).

†

Presence of the FIP1L1/PDGFRA fusion.

View Large